Champions Oncology to Announce Second Quarter Financial Results on Monday, December 15, 2025
Champions Oncology (NASDAQ:CSBR) will report financial and operational results for the second quarter ended October 31, 2025 on Monday, December 15, 2025 after market close.
Rhea-AI Summary
Champions Oncology (NASDAQ:CSBR) will report financial and operational results for the second quarter ended October 31, 2025 on Monday, December 15, 2025 after market close.
The company will host a conference call the same day at 4:30 P.M. EST (1:30 P.M. PST). Domestic dial-in: 888-506-0062; International: 973-528-0011; access code: 691139.
A replay will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) with passcode 53331, or via the company's investor website within 72 hours.
Positive
- None.
Negative
- None.
Details
News Market Reaction – CSBR
On Dec 9, the first trading day after this news, CSBR closed 0.16% above the previous close.
Data tracked by StockTitan Argus for the Dec 9 session.
Key Figures
- Earnings release date
- December 15, 2025
- Q2 results to be reported after market close
- Conference call time
- 4:30 P.M. EST
- Q2 results discussion on December 15, 2025
- Replay availability
- 72 hours
- Earnings call replay window via phone or website
Historical Context
-
Q1 FY2026 results with margin compression and shift to operating loss.
-
Q1 FY2026 revenue flat, higher expenses drove operating loss and lower EBITDA.
-
Scheduled Q1 fiscal 2025 results and conference call details.
-
Record FY2025 revenue and profitability but softer Q4 performance metrics.
-
Announcement of Q4 and year-end release date and investor call access.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HACKENSACK, NJ / ACCESS Newswire / December 8, 2025 / Champions Oncology, Inc. (CSBR), a leading translational oncology research organization, will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 691139. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 53331, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.
Media Inquiries:
Gavin Cooper - Vice President, Global Marketing
gcooper@championsoncology.com
Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.